Autoimmune Diseases  >>  Rebif (human IFN-β-1a)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

17 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rebif (human IFN-β-1a) / EMD Serono
NCT00292266: A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

Completed
3
677
US
Rebif®, Avonex®
EMD Serono, Merck Serono International SA
Multiple Sclerosis, Relapsing-Remitting
06/02
06/02
NCT00292253: Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects

Completed
3
1883
US
Rebif® via Rebiject™Mini, Rebif® via manual injections
EMD Serono, Merck Serono International SA
Multiple Sclerosis, Relapsing-remitting
12/02
12/02
RNF, NCT00110396 / 2004-003799-13: Rebif New Formulation () in Relapsing Forms of Multiple Sclerosis

Completed
3
260
US
Interferon-beta-1a FBS-free/HSA-free
EMD Serono, Pfizer
Multiple Sclerosis
04/07
04/07
REFORMS, NCT00428584: RNF and Betaseron® Tolerability Study

Checkmark P3 data: REFORMS
Dec 2012 - Dec 2012: P3 data: REFORMS
Completed
3
129
US
New Formulation of rebif - human interferon beta-1a, Interferon beta -1b
EMD Serono, Pfizer
Relapsing Remitting Multiple Sclerosis (RRMS)
11/07
09/09
TRANSFER, NCT00619307 / 2006-005972-42: Transition to Rebif New Formulation

Completed
3
117
Europe
Rebif New Formulation + prophylactic Ibuprofen, Rebif New Formulation + ibuprofen PRN
Merck KGaA, Darmstadt, Germany
Relapsing Multiple Sclerosis
04/08
04/08
IMPROVE, NCT00441103 / 2006-003037-32: A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

Completed
3
180
Canada, Europe, RoW
Rebif® New Formulation (IFN-beta-1a, RNF), IFN-beta-1a, Placebo
Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
11/08
02/09
NCT00735007 / 2008-000499-25: 12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

Completed
3
106
US, Canada, Europe
Rebif® New Formulation (RNF) using RebiSmartTM
EMD Serono
Multiple Sclerosis
01/09
 
RebiQoL, NCT00472797: Rebif New Formulation (RNF) Quality of Life (QOL) Study

Completed
3
232
US
Rebif New Formulation Non Titrated, Rebif New Formulation Titrated
EMD Serono
Relapsing Multiple Sclerosis
02/09
11/09
NCT00958009: The Multicenter, Open-label, Single-use Autoinjector Convenience Study

Checkmark CMSC 2015
Jun 2015 - Jun 2015: CMSC 2015
Completed
3
109
US
Rebidose®
EMD Serono
Multiple Sclerosis
04/10
06/10
REFLEX, NCT00404352 / 2006-002982-38: REbif FLEXible Dosing in Early Multiple Sclerosis (MS)

Checkmark REFLEX
Jan 2014 - Jan 2014: REFLEX
Checkmark REFLEX
Dec 2013 - Dec 2013: REFLEX
Checkmark Data, MS
More
Completed
3
517
Canada, Europe, RoW
RNF, Rebif, Placebo
Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
08/10
07/11
Performs, NCT01036165: A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study

Checkmark AAN 2015: Multiple sclerosis (PERFORMS)
Mar 2015 - Mar 2015: AAN 2015: Multiple sclerosis (PERFORMS)
Completed
3
103
US
RebiSmart™
EMD Serono
Multiple Sclerosis
08/10
08/10
CARE-MS I, NCT00530348 / 2007-001161-14 / ACTRN12608000435381: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

Checkmark CARE-MS I trial
Nov 2015 - Nov 2015: CARE-MS I trial
Checkmark ECTRIMS 2015: Multiple sclerosis (CARE-MS I extension)
Sep 2015 - Sep 2015: ECTRIMS 2015: Multiple sclerosis (CARE-MS I extension)
Checkmark CARE-MS I & CARE-MS II
More
Completed
3
581
US, Canada, Europe, RoW
Alemtuzumab, Lemtrada, Interferon beta-1a, Rebif®
Genzyme, a Sanofi Company, Bayer
Multiple Sclerosis, Relapsing-Remitting
04/11
04/11
REFLEXION, NCT00813709 / 2008-004954-34: Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)

Checkmark AAN 2015: Multiple sclerosis (REFLEX/REFLEXION)
Mar 2015 - Mar 2015: AAN 2015: Multiple sclerosis (REFLEX/REFLEXION)
Checkmark Data
Apr 2012 - Apr 2012: Data
Completed
3
402
Canada, Europe, RoW
RNF, Rebif®, Placebo
Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Clinically Isolated Syndrome
08/11
09/13
CARE-MS II, NCT00548405 / 2007-001162-32 / ACTRN12608000426381: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

Checkmark AAN 2016: CARE-MS II
Mar 2016 - Mar 2016: AAN 2016: CARE-MS II
Checkmark ECTRIMS 2015: Multiple sclerosis (CARE-MS II)
Sep 2015 - Sep 2015: ECTRIMS 2015: Multiple sclerosis (CARE-MS II)
Checkmark CMSC 2015
More
Completed
3
840
US, Canada, Europe, RoW
Alemtuzumab 12 mg, Lemtrada, Alemtuzumab 24 mg, Interferon beta-1a, Rebif®
Genzyme, a Sanofi Company, Bayer
Multiple Sclerosis, Relapsing-Remitting
09/11
09/11
TENERE, NCT00883337 / 2008-006226-34: A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis

Checkmark ISPOR: TENERE
Nov 2014 - Nov 2014: ISPOR: TENERE
Checkmark TENERE
Oct 2013 - Oct 2013: TENERE
Checkmark Data - ENS 2012
More
Completed
3
324
Canada, Europe, RoW
Interferon β-1a, Rebif®, Teriflunomide, HMR1726
Sanofi
Multiple Sclerosis
09/11
05/15
SURPASS, NCT01058005 / 2009-015556-15: Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Checkmark Interim data
Oct 2010 - Oct 2010: Interim data
Terminated
3
84
US, Canada, Europe, RoW
BG00002 (natalizumab), Tysabri, interferon beta-1a, Rebif, glatiramer acetate, Copaxone
Biogen, Elan Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
04/12
04/12
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21

Download Options